Statement: The only adverse event recorded in the primary trial was one single case of pleural effusion.
Primary_evidence: Adverse Events 1:   Total: 1/3 (33.33%)   FEBRILE NEUTROPENIA 0/3 (0.00%)   LYMPH NODE PAIN 0/3 (0.00%)   NEUTROPHIL COUNT DECREASED 0/3 (0.00%)   THROMBOCYTOPENIA 0/3 (0.00%)   CHEST PAIN 0/3 (0.00%)   DEHYDRATION 0/3 (0.00%)   PLEURAL EFFUSION 1/3 (33.33%)   PNEUMONITIS 0/3 (0.00%)   PULMONARY INFILTERATES 0/3 (0.00%)   ALOPECIA 0/3 (0.00%)